Mario Boccadoro

TL;DR: Palumbo et al. as mentioned in this paper found that miR-130a was decreased in serum samples of patients developing extramedullary (EM) disease and distinguished EM pts from newly diagnosed multiple myeloma (MM) patients with specificity over 90%.

TL;DR: An exploratory analysis of the treatment assignment of 162 newly diagnosed patients younger than 65 years was based only on the presence/absence of an HLA-identical sibling, and results indicate that del(13) does not offset the advantage in OS and EFS for patients with an HCA, but do not exclude an impact of del( 13) in those patients undergoing an allograft.

TL;DR: Overall, Seventy-eight of 83 patients with acute lymphoblastic leukemia achieved complete remission after induction, although 53% of them eventually relapsed, and the independent predictors of OS and EFS were age and leukocytosis in the overall population and allografting in young patients.

TL;DR: A BM biopsy showing LPL infiltration is currently essential to define WM; nevertheless, sometimes the pathological diagnosis can be troublesome and both the risk of relapse and the novel drugs are still difficult to predict in WM.

TL;DR: This study suggests that, in patients with newly diagnosed MM treated with bortezomib or lenalidomide combinations, infections are a frequent cause of morbidity but not of mortality.